摘要
目的:观察肠镜下植入氟尿嘧啶缓释剂治疗结肠癌疗效及安全性。方法:对80例诊断为结肠癌的患者进行临床分组观察治疗,观察组手术前在肠镜下植入氟尿嘧啶缓释剂,对照组常规手术操作。观察两组术后毒副反应、肿瘤复发情况以及3年生存率。结果:毒副作用方面,两组术后白细胞(WBC)、谷丙转氨酶(ALT)、血肌酐(Scr)均有一定程度的上升,但两组比较,差异无统计学意义(P>0.05)。肿瘤复发方面,Dukes C期患者,观察组复发率明显低于对照组(P<0.05)。生存期方面,1年生存率方面,两组无统计学差异(P>0.05),2年及3年生存期,观察组明显高于对照组(P<0.05)。结论:肠镜下植入氟尿嘧啶缓释剂治疗结肠癌毒副反应低,能够有效减低Dukes C期患者局部肿瘤复发率,提高患者2、3年临床生存率。
Objective：To observe effect of implantation of fluorouracil sustained-release agent under colonoscopy on treatment of colon cancer.Methods：Eighty patients who were diagnosed as colon cancer were randomly divided into control group and observation group.Patients in observation were implanted with fluorouracil sustained-release agent under colonoscopy before surgery,while patients in control group had only routine surgery.Postoperative toxicity,tumor recurrence,and 3-year survival rate were observed and compared.Results：Toxic and side-effect,postoperative white blood cell,alanine aminotransferase,serum creatinine were increased more or less,but the difference was not significant（P0.05）.The relapse rate of observation group was significantly lower than that of control group（P0.05）.There was no significant difference in 1-year survival rate,but 2and 3-year survival was significantly higher in observation group than control group（P0.05）.Conclusion：Implantation of fluorouracil sustained-release agent under colonoscopy is of few side effect.It can effectively reduce Dukes C with local tumor recurrence rate and improve the 2,3-year clinical survival rate.
出处
《海南医学院学报》
CAS
2013年第9期1286-1288,1291,共4页
Journal of Hainan Medical University
基金
广西自治区桂林市科技攻关与新产品试制科研基金(20110119-5)~~
关键词
肠镜
氟尿嘧啶缓释剂
结肠癌
Colonoscopy
Fluorouracil sustained-release agent
Colon cancer
